Mental disorders of the depressive and anxiety spectrum in neuroendocrine tumors: prevalence, pathogenesis, clinical particulars
-
Published:2024-09-10
Issue:3
Volume:52
Page:178-187
-
ISSN:2587-9294
-
Container-title:Almanac of Clinical Medicine
-
language:
-
Short-container-title:Almanac of Clinical Medicine
Author:
Kolyago Oleg O.ORCID, Munirova Adele A.ORCID, Ivanov Stanislav V.ORCID, Stilidi Ivan S.ORCID
Abstract
Neuroendocrine tumors (NETs) are a heterogeneous group of slowly progressing tumors from neuroendocrine cells able to secrete biologically active substances. The most striking clinical manifestation of functioning NETs is the carcinoid syndrome, which is caused by serotonin overproduction and is most often associated with hot flashes, diarrhea, and abdominal pain. The prevalence of depressive and anxiety spectrum disorders in NETs patients can amount to 30–50%. The development of depressive and anxiety spectrum disorders in NETs can occur both through a nosogenic mechanism facilitated by a long pre-diagnostic stage, the presence of a serious disease with severe somatic symptoms and resulting significant decrease in quality of life. The mental disorders may be a result of somatogenic factors, which include an imbalance of significant mediators in the central nervous system (in particular, serotonin), as well as chronic inflammation and abnormalities of the body's immune defense. In the treatment of patients with NETs and verified anxiety and depressive disorders, special attention is paid to the safety of prescribing the first-line therapy, the selective serotonin reuptake inhibitors. The side effects of these agents are related to the activity of serotonin receptor agonists in the gut, which results in diarrhea and increased gastrointestinal motility, the symptoms similar to the carcinoid syndrome manifestations. The accumulated evidence allows concluding on the relative safety of serotoninergic antidepressants in NETs patients, but does not exclude some groups of patients with an increased risk of complications related to an additional effect on serotonin metabolism. Current knowledge on the prevalence, pathogenesis and treatment of depressive and anxiety spectrum disorders, comorbid to NETs, are limited and contradictory. Therefore, further studies with a larger patient samples are required to identify key factors of the pathophysiology and manifestation of mental disorders in NETs patients, which would generally facilitate the optimization of their treatment.
Publisher
Moscow Regional Research and Clinical Institute (MONIKI)
Reference45 articles.
1. Gastroenteropancreatic neuroendocrine tumours 2. The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors 3. The archaic distinction between functioning and nonfunctioning neuroendocrine neoplasms is no longer clinically relevant 4. Alekseeva TR, Beltsevich DG, Bokhyan VYu, Bychkov MB, Byakhova MM, Vasilyev IA, Virshke ER, Voronkova IA, Vorotnikov IK, Gorbunova VA, Gurevich LE, Gutorov SL, Demidov LV, Dolgushin BI, Drapun SV, Drzheva LG, Egorov AV, Emelyanova GS, Eremkina AK, Zamolodchikov RD, Zolotareva TG, Ivanova AK, Kaldarov AR, Karmazanovsky GG, Karnaukhov NS, Kasprzyk SM, Keith OI, Kolesnikov EN, Komarova LE, Kondrashin SA, Kosyrev VYu, Kochatkov AV, Krieger AG, Krupinova YuA, Kuvshinov YuP, Kuzminov AE, Lapteva MG, Lozovaya VV, Lysanyuk MV, Lyubimova NV, Moistrenko NA, Malikhova OA, Mamedova EO, Markovich AA, Meshcheryakova MYu, Mokrysheva NG, Musaev GH, Nazarova VV, Nepomnyashchaya EM, Novikova OYu, Odzharova AA, Odintsova AS, Orel NF, Orlova KV, Oshkina EV, Panova NH, Patyushko YI, Peregorodtsev IN, Pirogova NA, Poddubny BK, Podluzhny DV, Polotsky BE, Potkina ON, Prostov MYu, Pshevlotsky EM, Pshichenko SV, Raikhlin IT, Rodionova MV, Rozhinskaya LYa, Romashchenko PN, Roslyakova AA, Sergeeva ON, Smirnova EA, Snezhko AV, Solodinina EH, Stilidi IS, Suraeva SA, Tabolinovskaya TD, Timofeev YuS, Timoshkina NN, Trifonov VS, Feydorov IYu, Filopenko DA, Fominykh EV, Khokhlova SV, Chekini AK, Chernyak MN, Chistyakova OV, Chichikov EI, Chukhrai OYu, Chkhikeadze NV, Shiryaev SV, Yastrebova ES, Borisova EI, Delectorskaya VV, Mamedov BB. [Neuroendocrine tumors. General principles of diagnosis and treatment]. Moscow: GEOTAR-Media, 2021. Russian. doi: 10.33029 9704-5997-3. 5. Salvia AS, Pomeri AP, Persano I, Trevisi E, Parlagreco E, Colombi N, Brizzi MP, Picci RL, Oliva F. Serotoninergic brain dysfunction in neuroendocrine tumor patients: A scoping review. Compr Psychiatry. 2021;109:152244. doi: 10.1016/ j.comppsych.2021.152244.
|
|